By Shalini Bhardwaj

Ahmedabad (Gujarat) [India], March 15 (ANI): Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market Colestipol Hydrochloride Tablets in the strength of 1mg (US RLD: Colestid), said the pharmaceutical company on Monday.

Also Read | Sandeep Singh, International Kabbadi Player, Shot Dead By Assailants in Punjab’s Jalandhar.

As per the statement issued by the company, Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet.

Colestipol Hydrochloride is a highly complex macromolecule drug substance with little or no systemic absorption, stated the company.

Also Read | Rajnath Singh to Address Parliament Tomorrow on Accidentally-Fired Missile That Landed in Pakistan.

It further said that Zydus' abbreviated new drug application (ANDA) is only the second generic application approved by USFDA for this product.

The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, stated the company.

The group now has 330 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04, it added. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)